Tiotropium Associated With Reduced All-Cause Mortality in Patients With COPD
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Tiotropium Associated With Reduced All-Cause Mortality in Patients With COPD

SAN DIEGO -- January 6, 2010 -- A study published in the January issue of the journal Chest suggests that tiotropium, a long-acting anticholinergic used in patients with chronic obstructive pulmonary disease (COPD), may be associated with a reduction in all-cause mortality, cardiovascular mortality, and cardiovascular events.

Bartolome Celli, MD, Pulmonary Critical Care Division, Brigham and Women’s Hospital, Boston, Massachusetts, and colleagues reviewed the outcomes of 30 completed clinical trials in the tiotropium project database.

Within the 30 trials that were analysed, 10,846 patients with COPD were randomised to receive treatment with tiotropium and 8,699 patients were randomised to receive a placebo.

Results indicated that patients treated with tiotropium had lower incidence rates (IR) of all-cause mortality, cardiovascular mortality, and cardiovascular events (IR = 3.44, .91, and 2.15 per 100 patients, respectively), compared with placebo (IR = 4.10, 1.24, and 2.67, respectively).

Within the tiotropium group, the overall risk for serious or fatal lower respiratory events also was reduced.

The mechanism by which tiotropium may reduce cardiovascular mortality is unclear, but researchers speculate that there may be an association with the reduction in respiratory events.

SOURCE: American College of Chest Physicians

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities